Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Clinical benefits appeared early, with noticeable separation between groups as early as week 4
It also has a growing research base, with work looking at how engaging these three pathways together shapes metabolic and insulin signaling (Coskun et al., 2022, Cell Metabolism)
Poor sleep depletes it
Heres what current studies show: People taking the highest dose of retatrutide (12 mg) in the latest phase 3 trial lost an average of about 24% of their body weight in about 68 weeks
Users can expect an average weight reduction of about 15%, with more than 80% of users experiencing significant decreases after just 12 months
This patent expires August 2033
US$ 22.32
US$ 21.01
US$ 28.10
US$ 27.29
US$ 21.82
US$ 25.52
US$ 21.34
